FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to methods of obtaining heteroaryl compounds, represented by structural formulae
(I) or
(II): where R1-R4 have values, given in subcl. 1,14 of the formula.
EFFECT: compounds can be used for treatment or prevention of cancer, inflammatory states, immunological states, etc.
29 cl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MTOR KINASE INHIBITORS FOR ONCOLOGIC INDICATIONS AND DISEASES ASSOCIATED WITH MTOR/PI3K/AKT BY METABOLISM | 2009 |
|
RU2692796C2 |
| mTOR KINASE INHIBITORS FOR ONCOLOGICAL INDICATIONS AND DISEASES METABOLICALLY BOUND TO mTOR/PI3K/AKT | 2009 |
|
RU2546658C2 |
| BIOMARKER ANALYSIS FOR DETECTING OR MEASURING TOR-KINASE ACTIVITY INHIBITION | 2011 |
|
RU2587040C2 |
| IDENTIFICATION OF LKB1 MUTATION AS PROGNOSTIC BIOMARKER OF SENSITIVITY TO TOR-KINASE INHIBITORS | 2011 |
|
RU2565034C2 |
| HETEROARYL COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING WITH USE OF SUCH COMPOUNDS | 2007 |
|
RU2478635C2 |
| IMIDAZOTRIAZINONE COMPOUNDS | 2011 |
|
RU2603140C2 |
| AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
| DNA-DEPENDENT PROTEIN KINASE INHIBITOR | 2020 |
|
RU2835434C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE LIGANDS OF DOPAMINE RECEPTORS D3 | 2017 |
|
RU2712455C1 |
Authors
Dates
2015-07-20—Published
2010-10-22—Filed